24 results about "Cell mediated immunity" patented technology

The invention relates to the field of medicine, more specifically to treatment of a condition associated with CD4+ T cell-mediated overactivation of the immune system.

Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

Provided herein are D domain-containing polypeptides that specifically bind to a target of interest, such as nucleic acids encoding the D domain-containing polypeptides, vectors containing the nucleic acids, and host cells containing the nucleic acids and vectors. Also provided herein are methods for producing and using D domain-containing polypeptides, nucleic acids, vectors, and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multifunctional chimeric antigen receptor (CAR)-based compositions and adapters, and their use in methods for directing an immune response against target cells. In some embodiments, the method includes the use of CAR-expressing cells in combination with an adapter. The adapter confers the ability to modulate, alter, and / or direct the cell-mediated immune response of the CAR-expressing cells in vitro and in vivo.

The application discloses a CD40L-IL-2 fusion protein and a preparation method and application thereof in preparing a tumor treatment drug. The fusion protein comprises a CD40L trimer or a variant thereof and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers connected. The fusion protein provided by the application can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing, forms a closed-loop anti-tumor immune response of 'antigen presentation-immune initiation-effect amplification', and provides an effective strategy for treating tumors.

The invention discloses a combined application of a PARP7 inhibitor or a pharmaceutically acceptable salt thereof and temozolomide, which is characterized in that the PARP7 inhibitor is used for recovering an I-type interferon signal channel and promoting T cell-mediated immune response and polarization of TAMs to M1 type, so that the side effect of temozolomide is reduced, the sensitivity of temozolomide is enhanced, and an excellent synergistic anti-tumor effect is achieved; the traditional Chinese medicine composition especially has a remarkable curative effect on brain glioma with high malignant degree, and is safe and effective.

This invention relates to the field of pharmaceutical technology, specifically proposing the application of ligustilide in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating lung tumors to address the current lack of natural drugs for lung cancer prevention. Lung tumors are nitrosamine-induced carcinogenesis of lung tissue. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or alleviating and / or treating lung tumors, comprising an active ingredient and pharmaceutically acceptable excipients; wherein the active ingredient is ligustilide. Ligustilide directly targets the STING protein, activates the cGAS-STING pathway, promotes STING phosphorylation and cell-mediated immune surveillance, while simultaneously regulating ROS homeostasis and the inflammatory microenvironment, reducing nitrosamine damage to lung epithelial cells, and preventing nitrosamine-induced lung carcinogenesis.

This invention provides transformed cells for the production of transformed replica pigs for xenotransplantation. [Solution] This invention relates to a transformed replica pig from which the heterologous antigens GGTA1, CMAH, iGb3s, β4GalNT2, and β2M genes have been removed from a PERV Envelope C-negative base, and a method for producing the same. The transformed replica pig according to the present invention can overcome hyperacute and antigen-antibody-mediated immune rejection reactions and T-cell-mediated immune rejection reactions without causing the transfer of porcine endogenous retroviruses that occur in xenologous organ transplantation, and can be usefully utilized as a donor animal for interspecies organ and cell transplantation.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and / or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The present application relates to a kind of anti-PD-L1 and HHLA2 bispecific antibody and its preparation method and application.The bispecific antibody includes PD-L1 binding domain and HHLA2 binding domain, the PD-L1 binding domain includes anti-PD-L1 monoclonal antibody, the HHLA2 binding domain includes the variable region of anti-HHLA2 nanobody;The variable region of anti-HHLA2 nanobody is connected with the N terminal or C terminal of the light chain or heavy chain of anti-PD-L1 monoclonal antibody by flexible linker.The present application constructs specific structure anti-HHLA2 and PD-L1 bispecific antibody, with high specificity and affinity, can up-regulate cell-mediated immune response, and enhance the function of T cell and NK cell in tumor microenvironment.In addition, bispecific antibody drug conjugate can be further developed, with higher efficient tumor cell specific killing ability, provide new method, new idea for treating tumor and infectious disease.

A composition that modulates cellular immunity in animals includes an ingredient derived from a plant. Such an ingredient may be referred to as “plant-derived” or “plant-based.” The plant-derived ingredient modulates cellular immunity in animals. Such a plant-derived ingredient may include an extract, fraction, or isolate from a seed of a plant, such as a seed of a plant from the family Brassicaceae. A method for modulating cellular immunity in an animal includes administering a plant-derived composition to the animal in amount that will cause the animal to elicit a cell-mediated immune response.

The present invention provides bispecific binding proteins binding MUC-1 and CD40 and pharmaceutical compositions, and their use to upregulate cell-mediated immune responses and for the treatment of cancer.

Provided herein are compositions and methods for inducing an immune response using small circular ribonucleic acid (circRNA) molecules. In particular, the compositions comprise a small circRNA encoding at least one antigen or immunogenic peptide fragment, wherein the composition is self-adjuvanted and configured to elicit a T-cell–mediated immune response.

The present invention pertains to a ribonucleic acid (RNA)-based vaccine for immunizing equine subjects, particularly foals, against equine rotavirus. More specifically, the present invention provides for a mRNA vaccine that contains an open reading frame (ORF) encoding an immunogenic or antigenic viral peptide or polypeptide, such as virulence-associated protein A (VapA), which, when administered to an equine subject, will induce a humoral response and / or a cell-mediated immune (CMI) response against a pathogenic equine rotavirus.

This disclosure provides compositions and methods for T-cell mediated depletion of B cells. The compositions and methods may be used, for example, for the treatment of autoimmune disorders, immune-mediated inflammation disorders and other B-cell mediated immune disorders. In embodiments, the depletion is effected by methods comprising administering to an individual a T cell engaging protein ("TEP"), wherein the TEP comprises: (i) a peptide-major histocompatibility complex ("pMHC") comprising a peptide epitope, a β2-microglobulin ("β2M") polypeptide, and an MHC class I heavy chain polypeptide; (ii) an immunoglobulin ("Ig") Fc polypeptide; (iii) at least one B-cell targeting component; and (iv) optionally one or more activating immunomodulatory polypeptides, wherein each of the at least one B-cell targeting components of the TEP binds to a B cell binding partner on a B cell, a plasmablast, and / or a plasma cell.

Methods of treating a subject with cancer with CD8 T cell-mediated immune therapy are provided. The methods include measuring an amount of CXCR3-positive T cells in a peripheral blood sample or a tumor sample from a subject with cancer following treatment of the subject with at least one dose of the CD8 T cell-mediated therapy and comparing the amount of CXCR3-positive T cells in the sample to a control. Responsiveness of the cancer to the CD8 T cell-mediated therapy is predicted based on whether there is an increase or decrease in the amount of CXCR3-positive T cells in the sample. Methods further including treating the subject with at least one additional dose of the CD8 T cell-mediated immune therapy are also provided.

The present application provides molecules comprising antibodies that bind to T cell receptors (TCRs). In particular, the present application provides antibodies that bind to human [gamma] [delta] TCR wherein these human [gamma] [delta] T cells can be activated and modulated. The present application also provides bispecific tumor-targeting immunomodulators that bind to both tumor-associated antigens and gamma delta T cell receptors and enhance cell-mediated immune responses in the treatment of cancer. Also provided are methods of making these antibodies and methods of using these antibodies to kill cancer cells.

The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and / or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

The invention is based on the use of mitophagy agonists as defined in the claims, in particular Urolithin A, for improving mitochondrial health in immune cells such as T-cells. The invention provides new strategies to enhance immune cell based therapies, such as adoptive T-cell therapy. The compounds and compositions of the invention are preferably useful for therapies that involve in vitro T cell modification and expansion, such as modification of T cells with a chimeric antigen receptor (CAR) for treating an antigen associated disorder, such as cancer.

The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

The invention belongs to the field of gene engineering, and particularly relates to a construction method of a lactic acid-consuming gene engineering strain, a related product and application of the lactic acid-consuming gene engineering strain in tumor treatment. Probiotics with tumor targeted colonization capability are taken as an original strain, CRISPR-Cas9 mediated homologous recombination transformation is carried out, glk is knocked out and an lldD gene is inserted, ldhA is knocked out and a dld gene is inserted, and the genes are driven by a pJ23119 promoter. The modified engineering bacteria can be colonized in tumor tissues in a targeted manner, efficiently metabolize lactic acid in a tumor microenvironment and effectively relieve local acidosis, so that immune cell activation is promoted, and the Treg cell mediated immunosuppression effect is weakened. In animal models of melanoma and colon cancer, when the engineering bacterium is combined with an anti-PD-1 antibody for use, a remarkable synergistic tumor inhibition effect is shown, obvious systemic toxicity is not observed, and a safe and effective new strategy is provided for tumor treatment.

The present invention pertains to a ribonucleic acid (RNA)-based vaccine for immunizing equine subjects, particularly foals, against Rhodococcus equi (RE) pneumonia (referred to herein as a RE vaccine). More specifically, the present invention provides for a mRNA vaccine that contains an open reading frame (ORF) encoding an immunogenic or antigenic bacterial peptide or polypeptide, such as virulence-associated protein A (VapA), which, when administered to an equine subject, will induce a humoral response and / or a cell-mediated immune (CMI) response against the respiratory pathogen RE.